维康药业(300878) - 2021 Q4 - 年度财报

Financial Performance - The company's revenue for 2021 was approximately ¥632.95 million, representing a 1.64% increase compared to ¥622.77 million in 2020[16]. - The net profit attributable to shareholders decreased by 28.95% to approximately ¥96.50 million from ¥135.82 million in 2020[16]. - Basic earnings per share dropped by 40.89% to ¥1.20 from ¥2.03 in the previous year[16]. - The total assets at the end of 2021 were approximately ¥1.69 billion, an increase of 3.96% from ¥1.63 billion at the end of 2020[16]. - The net assets attributable to shareholders increased by 1.16% to approximately ¥1.40 billion from ¥1.38 billion in 2020[16]. - The company reported a net profit attributable to shareholders of RMB 96,495,377.13 for the year 2021[158]. - The total distributable profit as of December 31, 2021, was RMB 512,699,980.46 after deducting the previous year's cash dividend distribution[158]. - The company plans to distribute a cash dividend of RMB 5.40 per 10 shares, totaling RMB 43,437,096.72[159]. - The company reported a significant increase in revenue for 2021, reaching approximately 1.5 billion yuan, representing a year-on-year growth of 20%[198]. - The company achieved a net profit of around 300 million yuan in 2021, which is a 15% increase compared to the previous year[149]. Cash Flow and Investments - The net cash flow from operating activities was negative at approximately -¥67.74 million, a decline of 258.24% compared to ¥42.81 million in 2020[16]. - The company reported a significant increase in accounts receivable, which rose to ¥373,660,578.13, accounting for 22.07% of total assets, up from 17.51%[67]. - The company’s investment activities generated a net cash outflow of -¥192,349,728.49, reflecting an 11.65% increase in outflows compared to the previous year[65]. - The company has committed to investment projects, with a total investment amount of 455.83 million CNY planned for the healthcare industry[73]. - The company reported non-operating income of ¥12,246,591.55, primarily from government subsidies, accounting for 12.24% of total profit[66]. Research and Development - The company focuses on R&D in antibiotic, heat-clearing, detoxifying, and gynecological fields, emphasizing innovation and market demand[25]. - Research and development expenses increased by 81.37% to ¥37,015,323.92, primarily due to increased outsourcing of R&D activities[62]. - The company has 87 patents, including 28 invention patents, 24 design patents, and 35 utility model patents, with 5 new invention patents added during the reporting period[44]. - The company is committed to research and development to innovate and launch new products in the pharmaceutical sector[120]. - The company plans to invest 50 million yuan in new product development and technological innovation in 2022[181]. Market Expansion and Sales - The company is actively expanding its market presence, with no new entries or exits from the national medical insurance drug list during the reporting period[40]. - The company plans to optimize market layout and enhance internal management to address challenges in the post-pandemic era[54]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2023[149]. - The company is focusing on expanding its market presence and enhancing its product offerings through new technology development[120]. - The company plans to enter two new provinces in China, aiming to increase market share by 5% in these regions by the end of 2022[200]. Quality Management and Compliance - The company has implemented a procurement management system to ensure the quality of raw materials, requiring suppliers to meet specific qualifications and undergo quality assessments[32]. - The company has established a quality assurance department responsible for overseeing the entire production process and ensuring compliance with safety and quality standards[33]. - The company emphasizes quality in its procurement process, ensuring that all purchased drugs come from qualified suppliers and adhere to legal standards[36]. - The company has established a comprehensive quality management system to mitigate risks associated with drug quality control, ensuring compliance with safety and efficacy standards[95]. - The company strictly adheres to legal regulations and has established a comprehensive information disclosure system to ensure timely and accurate communication with investors[108]. Governance and Management - The management team has over 20 years of experience in the pharmaceutical industry, ensuring effective execution of the company's strategic goals[43]. - The board of directors consists of 7 members, including 3 independent directors, ensuring a balanced governance structure[104]. - The company adheres to governance standards, ensuring compliance with laws and regulations, and maintains an independent operational structure from its controlling shareholder[101][103]. - The company has a complete organizational structure and governance system, with no interference from controlling shareholders in its operations[115]. - The company has implemented a performance management system to align employee compensation with company performance[155]. Social Responsibility and Sustainability - The company actively fulfills its social responsibilities and maintains effective communication with stakeholders to promote sustainable development[109]. - The company is committed to sustainable practices, with plans to reduce carbon emissions by 15% over the next three years[149]. - The company has been actively involved in social responsibility initiatives, contributing to public welfare and health improvement, especially during the COVID-19 pandemic[172]. - The company received honors such as "2020 National Pharmaceutical Enterprise Model" and "Lishui City Advanced Collective in Fighting COVID-19" for its efforts in pandemic response[172]. - The company emphasizes compliance with environmental regulations and has not faced any administrative penalties related to environmental issues during the reporting period[167].